HomeCompareASPCF vs GBDC

ASPCF vs GBDC: Dividend Comparison 2026

ASPCF yields 909.59% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASPCF wins by $8291476.92M in total portfolio value
10 years
ASPCF
ASPCF
● Live price
909.59%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8291497.77M
Annual income
$6,817,159,983,407.13
Full ASPCF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ASPCF vs GBDC

📍 ASPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASPCFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASPCF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASPCF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPCF
Annual income on $10K today (after 15% tax)
$77,314.90/yr
After 10yr DRIP, annual income (after tax)
$5,794,585,985,896.06/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ASPCF beats the other by $5,794,572,002,772.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPCF + GBDC for your $10,000?

ASPCF: 50%GBDC: 50%
100% GBDC50/50100% ASPCF
Portfolio after 10yr
$4145759.31M
Annual income
$3,408,588,217,070.48/yr
Blended yield
82.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ASPCF
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPCF buys
0
GBDC buys
0
No recent congressional trades found for ASPCF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASPCFGBDC
Forward yield909.59%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$8291497.77M$20.85M
Annual income after 10y$6,817,159,983,407.13$16,450,733.83
Total dividends collected$8177275.77M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ASPCF vs GBDC ($10,000, DRIP)

YearASPCF PortfolioASPCF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$101,659$90,958.70$12,492$1,791.70+$89.2KASPCF
2$972,957$864,181.69$16,527$3,160.58+$956.4KASPCF
3$8,770,897$7,729,833.49$23,588$5,904.90+$8.75MASPCF
4$74,508,241$65,123,381.48$37,141$11,901.65+$74.47MASPCF
5$596,751,110$517,027,292.00$66,205$26,463.38+$596.68MASPCF
6$4,508,591,853$3,870,068,165.34$137,452$66,612.65+$4508.45MASPCF
7$32,150,599,702$27,326,406,419.03$342,372$195,298.53+$32150.26MASPCF
8$216,516,638,004$182,115,496,323.36$1,053,292$686,954.33+$216515.58MASPCF
9$1,377,885,778,910$1,146,212,976,244.92$4,111,439$2,984,416.95+$1377881.67MASPCF
10$8,291,497,766,840$6,817,159,983,407.13$20,849,974$16,450,733.83+$8291476.92MASPCF

ASPCF vs GBDC: Complete Analysis 2026

ASPCFStock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Full ASPCF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ASPCF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPCF vs SCHDASPCF vs JEPIASPCF vs OASPCF vs KOASPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.